. Differential role of sarcolemmal and mitochondrial K ATP channels in adenosine-enhanced ischemic preconditioning. Am J Physiol Heart Circ Physiol 279: H2694-H2703, 2000.-Adenosine-enhanced ischemic preconditioning (APC) extends the protection afforded by ischemic preconditioning (IPC) by both significantly decreasing infarct size and significantly enhancing postischemic functional recovery. The purpose of this study was to determine whether APC is modulated by ATP-sensitive potassium (K ATP ) channels and to determine whether this modulation occurs before ischemia or during reperfusion. The role of K ATP channels before ischemia (I), during reperfusion (R), or during ischemia and reperfusion (IR) was investigated using the nonspecific K ATP blocker glibenclamide (Glb), the mitochondrial (mito) K ATP channel blocker 5-hydroxydecanoate (5-HD), and the sarcolemmal (sarc) K ATP channel blocker HMR-1883 (HMR). Infarct size was significantly increased (P Ͻ 0.05) in APC hearts with Glb-I, Glb-R, and 5-HD-I treatment and partially with 5-HD-R. Glb-I and Glb-R treatment significantly decreased APC functional recovery (P Ͻ 0.05 vs. APC), whereas 5-HD-I and 5-HD-R had no effect on APC functional recovery. HMR-IR significantly decreased postischemic functional recovery (P Ͻ 0.05 vs. APC) but had no effect on infarct size. These data indicate that APC infarct size reduction is modulated by mitoK ATP channels primarily during ischemia and suggest that functional recovery is modulated by sarcK ATP channels during ischemia and reperfusion. stunning; myocardial protection; ATP-sensitive potassium channels WE REPORTED PREVIOUSLY (24-27, 38) that adenosineenhanced ischemic preconditioning (APC), in which a bolus injection of adenosine is used coincident with single-cycle ischemic preconditioning (IPC), extends and amends the cardioprotection afforded by IPC by both significantly decreasing myocardial infarct size (P Ͻ 0.05 vs. IPC) and significantly enhancing postischemic functional recovery (P Ͻ 0.05 vs. IPC) in both the isolated, perfused rabbit heart and in the in situ blood-perfused sheep heart. Recently, we showed (25) that APC-enhanced infarct size reduction is primarily modulated by adenosine receptors before ischemia, whereas APC-enhanced postischemic functional recovery is modulated by adenosine receptors both before ischemia and during reperfusion.
stunning; myocardial protection; ATP-sensitive potassium channels WE REPORTED PREVIOUSLY (24) (25) (26) (27) 38 ) that adenosineenhanced ischemic preconditioning (APC), in which a bolus injection of adenosine is used coincident with single-cycle ischemic preconditioning (IPC), extends and amends the cardioprotection afforded by IPC by both significantly decreasing myocardial infarct size (P Ͻ 0.05 vs. IPC) and significantly enhancing postischemic functional recovery (P Ͻ 0.05 vs. IPC) in both the isolated, perfused rabbit heart and in the in situ blood-perfused sheep heart. Recently, we showed (25) that APC-enhanced infarct size reduction is primarily modulated by adenosine receptors before ischemia, whereas APC-enhanced postischemic functional recovery is modulated by adenosine receptors both before ischemia and during reperfusion.
The downstream effector of adenosine receptor activation was shown previously to be ATP-sensitive potassium (K ATP ) channels that have been suggested to play a central role in IPC (4, 31, 32, 39) . Two K ATP channel subtypes exist in the myocardium, with one subtype located in the sarcolemma (sarcK ATP ) and the other in the inner membrane of the mitochondria (mitoK ATP ) (21) . SarcK ATP channels are inhibited by glibenclamide and selectively inhibited by HMR-1883 (2, 3, 11, 13) , whereas mitoK ATP channels are inhibited by glibenclamide and specifically inhibited by 5-hydroxydecanoate (33) . The involvement of K ATP channels in APC cardioprotection and the relevance and specificity of these channels during ischemia and reperfusion were unknown. The purpose of this study was to determine whether the cardioprotection afforded by APC was modulated by K ATP channels, to determine whether this modulation occurred before ischemia or during reperfusion, and to determine the specificity of K ATP channel modulation on APC cardioprotection during ischemia and reperfusion.
Our results indicate that the cardioprotection afforded by APC is modulated by K ATP channels. APC myocardial infarct size reduction is completely abolished by mitoK ATP channel blockade before ischemia. APC-enhanced postischemic functional recovery is not affected by mitoK ATP channel blockade before ischemia and/or during reperfusion. Blockade of sarcK ATP channels both before ischemia and during reperfusion significantly decreased APC-enhanced postischemic functional recovery [P Ͻ 0.05 vs APC; not significant (NS) vs. global ischemia]. These data suggest that infarct size is modulated by mitoK ATP channels primarily during ischemia, whereas postischemic functional recovery is modulated by sarcK ATP channels both during ischemia and reperfusion.
METHODS

Animals and chemicals.
New Zealand White rabbits (n ϭ 95; 15-20 wk, 3-4 kg) were obtained from Millbrook Farm (Amherst, MA). All animals were housed individually and provided with laboratory chow and water ad libitum. All experiments were approved by the Beth Israel Deaconess Medical Center Animal Care and Use Committee and the Harvard Medical Area Standing Committee on Animals (Institutional Animal Care and Use Committee) and conformed to the National Institutes of Health guidelines regulating the care and use of laboratory animals (NIH publication 1996) .
Langendorff perfusion. All rabbits were anesthetized with ketamine (33 mg/kg) and xylazine (16 mg/kg) and received heparin (200 U/kg) intravenously via a marginal ear vein (28, 40) . The heart was excised and placed in a 4°C bath of Krebs-Ringer solution equilibrated with 95% O 2 -5% CO 2 (pH 7.4 at 37°C), in which spontaneous beating ceased within a few seconds (26, 27) . Langendorff retrograde perfusion was performed as previously described (26, 27) . In brief, a latex balloon containing a catheter-tip transducer (Millar Instruments, Houston, TX) was inserted into the left ventricle and held in place by a purse-string suture. The volume of the water-filled balloon was maintained at a constant physiological end-diastolic pressure in the range of 5-10 mmHg using a calibrated microsyringe. The aorta was cannulated with a metal cannula, and the heart was subjected to Langendorff retrograde perfusion at a constant pressure of 75 cmH 2 O at 37°C. Hearts were paced via the right atrium at 180 Ϯ 3 beats/min throughout the experiment using a Medtronic model 5330 stimulator (Medtronic, Minneapolis, MN). Hemodynamic variables were acquired using the PO-NE-MAH digital data acquisition system (Gould, Valley View, OH) with an Acquire Plus processor board and left ventricular pressure analysis software.
Experimental protocol. Hearts were perfused for 18 min to establish equilibrium hemodynamics. Equilibrium was ended when heart rate, coronary flow, and left ventricular peak developed pressure (LVPDP) and end-diastolic pressure (LVEDP) had been maintained at the same level for three continuous measurement periods timed 5 min apart. Control hearts (n ϭ 8) were perfused without global ischemia at 37°C for 180 min. Global ischemia hearts (GI; n ϭ 8) were subjected to 30-min global ischemia and 120-min reperfusion. Global ischemia was achieved by cross-clamping the perfusion line. APC hearts (n ϭ 8) received a 10-ml bolus injection of 1 mM adenosine in Krebs buffer (Adenoscan; Medco, Research Triangle Park, NC) coincident with IPC (5-min zeroflow global ischemia followed by 5-min reperfusion). The bolus was injected into the aortic root via the sidearm of a cannula located proximal to the perfusion cannula.
Effect of K ATP channel blockers on functional recovery. To distinguish the effect of glibenclamide, 5-hydroxydecanoate, and HMR-1883 on APC cardioprotection from the persistent drug effect of glibenclamide, 5-hydroxydecanoate, and HMR-1883, control hearts were perfused separately with glibenclamide, 5-hydroxydecanoate, HMR-1883, or both 5-hydroxydecanoate and HMR-1883. Blockers were perfused for 7 min before global ischemia (from 18-20 min of perfusion to 25-30 min of perfusion) and for 2 min at the onset of reperfusion (R; 60-62 min of perfusion) (controlϩGlb/Glb-R, n ϭ 3; controlϩ5-HD/5-HD-R, n ϭ 3; controlϩHMR/HMR-R, n ϭ 3). In 5-HD-HMR/HMR-R hearts (n ϭ 3), 5-hydroxydecanoate and HMR-1883 were perfused for 7 min before global ischemia and HMR-1883 was perfused for 2 min at the onset of reperfusion.
Role of K ATP channels in APC cardioprotection during ischemia and reperfusion. To determine the role of K ATP channels in APC cardioprotection during ischemia and reperfusion, APC hearts were perfused separately with the nonselective K ATP channel blocker glibenclamide (18 M in Krebs-Ringer solution; Sigma Chemical, St. Louis, MO) for 2 min before APC and during the 5-min reperfusion before global ischemia (Glb; n ϭ 6) or for 2 min at the onset of reperfusion (Glb-R; n ϭ 5). The concentration of glibenclamide was determined based on preliminary investigations using serial glibenclamide concentrations based on the data of Hoag et al. (17) . A separate group of APC hearts were perfused with glibenclamide for 2 min before APC and during the 5-min reperfusion before global ischemia and for 2 min at the onset of reperfusion (Glb/Glb-R; n ϭ 6).
Role of specific K ATP channels in APC cardioprotection during ischemia and reperfusion. To determine the role of mitoK ATP channels in APC cardioprotection during ischemia and reperfusion, APC hearts were perfused separately with the rabbit heart selective mitoK ATP channel blocker 5-hydroxydecanoate (200 M, in Krebs-Ringer solution; Research Biochemicals, Natick, MA) for 2 min before APC and during the 5-min reperfusion before global ischemia (APCϩ5-HD; n ϭ 6) or for 2 min at the onset of reperfusion (APCϩ5-HD-R; n ϭ 6) (21) . A separate group of APC hearts were perfused with 5-hydroxydecanoate (200 M in Krebs-Ringer solution) for 2 min before APC and during the 5-min reperfusion before global ischemia and for 2 min at the onset of reperfusion (APCϩ5-HD/5-HD-R; n ϭ 6).
To determine the role of sarcK ATP channels in APC cardioprotection during ischemia and reperfusion, APC hearts were perfused separately with the selective sarcK ATP channel blocker HMR-1883 (50 M in Krebs-Ringer solution; the kind gift of H. C. Englert, Hoechst-Marion-Roussel, Frankfurt, Germany) for 2 min before APC and during the 5-min reperfusion before global ischemia (APCϩHMR; n ϭ 6) or for 2 min at the onset of reperfusion (APCϩHMR-R; n ϭ 6) (2, 3, 11, 13) . A separate group of APC hearts was perfused with HMR-1883 (50 M, in Krebs-Ringer solution) for 2 min before APC and during the 5-min reperfusion before global ischemia and for 2 min at the onset of reperfusion (APC ϩ HMR/HMR-R; n ϭ 6). A final group of APC hearts was perfused with 5-hydroxydecanoate (200 M, in Krebs-Ringer solution) and HMR-1883 (50 M, in Krebs-Ringer solution) for 2 min before APC and during the 5 min after APC, before global ischemia, and with HMR-1883 (50 M, in KrebsRinger solution) for 2 min at the onset of reperfusion (APCϩ5-HD-HMR/HMR-R; n ϭ 6).
Measurement of infarct size. Infarct size was determined as previously described using 1% triphenyltetrazolium chloride (Sigma Chemical) in phosphate buffer (pH 7.4) (18, 24, 26, 41) . Left ventricle area and the area of infarcted tissue were measured by an independent, blinded observer using computer planimetry as previously described (24-27, 37, 38) .
Wet weight-to-dry weight ratios. Left ventricular tissue samples (ϳ0.1 g) from all experimental groups were weighed (wet weight), dried at 80°C for 24 h for reweighing (dry weight), and then used for the determination of wet-to-dry weight ratios using previously described methods (26, 27) .
Statistical analysis. Statistical analysis was performed using SAS (version 6.12; SAS Institute, Cary, NC). Means Ϯ SE are reported in Tables 1-4 and in text. Statistical significance was assessed using repeated-measures analysis of variance with group as a between-subjects factor and time as a within-subjects factor. If this overall test was significant, one-way analysis of variance was performed at individual time points, and, when significant, post hoc comparisons were made between groups at a time point. Dunnett's test was used for comparisons between APC and other groups, because the primary focus was determination of which of the K ATP treatments were different from APC. Dunnett's test adjusts for the number of tests being performed but does not adjust for comparisons across all groups. Bonferroni correction was used for comparisons between groups other than APC. One-way analysis of variance was used for area of infarction. P Ͻ 0.05 was used for statistical significance.
RESULTS
Effect of K ATP channel blockers on functional recovery.
The results shown in Table 1 indicate that LVPDP and the positive first derivative of pressure over time (ϩdP/dt) were significantly decreased and LVEDP was significantly increased in controlϩGlb/Glb-R, controlϩ5-HD/5-HD-R, controlϩHMR/HMR-R, and controlϩ5-HD-HMR/HMR-R hearts (P Ͻ 0.05 vs. control and APC) at 20 min of perfusion and at 30 min of perfusion (after perfusion of K ATP channel blockers). No significant difference in LVPDP, LVEDP, ϩdP/dt, or coronary flow was observed within or between groups during 120-min reperfusion (NS vs. control and APC, Table 1 ).
Infarct size was 2.5 Ϯ 0.5% in controlϩGlb/Glb-R, 2.2 Ϯ 0.5% in controlϩ5-HD/5-HD-R, 1.7 Ϯ 0.2% in controlϩHMR/HMR-R, and 1.4 Ϯ 0.3% in controlϩ5-HD-HMR/HMR-R hearts. No significant difference in infarct size was observed within or between groups, and there was no significant difference between groups compared with control.
Equilibrium hemodynamics. No significant difference in LVPDP, ϩdP/dt, or coronary flow was observed within or between groups at the end of equilibrium (18 min of perfusion) ( Tables 2-4) .
Role of K ATP channels in APC cardioprotection during ischemia and reperfusion. LVPDP and ϩdP/dt were significantly decreased in APCϩGlb hearts (P Ͻ 0.05 vs. APC and APCϩGlb-R) at 20 min of perfusion (after 2-min perfusion of glibenclamide before APC; Table 2 ). After APC (30 min of perfusion), LVPDP and ϩdP/dt were significantly decreased in APCϩGlb hearts (P Ͻ 0.05 vs. APC and APCϩGlb-R). No significant difference in coronary flow was observed within or between groups at 30 min of perfusion, just before global ischemia.
LVPDP, ϩdP/dt, and coronary flow were significantly decreased in GI hearts (P Ͻ 0.05 vs. APC) Results are shown as means Ϯ SE; n ϭ 3 for each group. Functional data for control hearts perfused separately with the nonselective ATP-sensitive potassium (K ATP ) channel blocker glibenclamide (Glb), the rabbit heart selective mitochondrial K ATP (mitoK ATP ) channel blocker 5-hydroxydecanoate (5-HD), and the selective sarcolemmal K ATP (sarcK ATP ) channel blocker HMR-1883 (HMR) are shown. Blockers were perfused for 7 min before global ischemia and for 2 min at the onset of reperfusion (R). In Controlϩ5-HD-HMR/HMR-R hearts, 5-HD and HMR-1883 were perfused for 7 min before global ischemia and HMR-1883 was perfused for 2 min at the onset of reperfusion. Significant differences at P Ͻ 0.05 vs. control are noted with an asterisk. There was no significant difference in left ventricular (LV) peak developed pressure (LVPDP), LV end-diastolic pressure (LVEDP), positive first derivative of pressure over time (ϩdP/dt), or coronary flow observed within or between groups during 120-min reperfusion (70-180 min of perfusion).
during reperfusion (70-180 min of perfusion). LVPDP and ϩdP/dt were significantly decreased in APCϩGlb hearts (P Ͻ 0.05 vs. APC) throughout reperfusion (70-180 min of perfusion). Coronary flow was significantly decreased in APCϩGlb hearts (P Ͻ 0.05 vs. APC) at 70-90 min of perfusion. In APCϩGlb-R hearts, LVPDP was significantly decreased (P Ͻ 0.05 vs. APC) at 70-80 min of perfusion but was not significantly different from that observed in APC at 90-180 min of perfusion. LVPDP and ϩdP/dt were significantly decreased in APCϩGlb/Glb-R hearts (P Ͻ 0.05 vs. APC) throughout reperfusion (70-180 min of perfusion). No significant difference was observed between control and APC hearts.
Infarct size expressed as a percentage of ventricular volume was significantly increased to 32.9 Ϯ 5.1% in GI hearts (P Ͻ 0.05 vs. control and APC) compared with 1.0 Ϯ 0.3% in control hearts and 2.8 Ϯ 0.5% in APC hearts after 30 min of normothermic global ischemia and 120 min of reperfusion (Fig. 1) . Infarct size was significantly increased to 22.4 Ϯ 4.3% in APCϩGlb hearts and 28.8 Ϯ 1.1% in APCϩGlb/Glb-R hearts (P Ͻ Results are shown as means Ϯ SE; n ϭ 5-8 for each group. Functional data after equilibrium (18-min of perfusion), during adenosine-enhanced ischemic preconditioning (APC; 20-to 30-min perfusion; 5-min ischemia and 5-min reperfusion), during global ischemia (40-60 min of perfusion), and during reperfusion (70-180 min of perfusion), for control, global ischemia (GI), APC hearts, and APC hearts perfused with the nonselective K ATP channel blocker Glb for 2 min before APC and during the 5 min after APC, before GI (APCϩGLB) or for 2 min at the onset of reperfusion (APCϩGLB-R), or during both periods (APCϩGLB/GLB-R) are shown. Significant differences at P Ͻ 0.05 vs. APC are noted with an asterisk. Fig. 1 . Infarct size expressed as a percentage of ventricular volume after 30 min of global ischemia and 120 min of reperfusion in control, global ischemia (GI), and adenosine-enhanced ischemic preconditioning (APC) hearts and APC hearts perfused with the nonselective ATP-sensitive potassium (K ATP ) channel blocker glibenclamide for 2 min before APC and during the 5 min of reperfusion before global ischemia (APCϩGlb), for 2 min at the onset of reperfusion (APCϩGlb-R), or during both periods (APCϩGlb/Glb-R). Results are shown as means Ϯ SE; n ϭ 5-8 for each group. *Significant differences at P Ͻ 0.05 vs. APC hearts; **significant differences at P Ͻ 0.05 vs. GI hearts. There was no significant difference in infarct size between APC and control hearts. 0.05 vs. control, APC, and APCϩGlb-R; NS vs. GI). Infarct size was 14.0 Ϯ 1.5% in APCϩGlb-R hearts (P Ͻ 0.05 vs. APCϩGlb, APCϩGlb/Glb-R, APC, and GI). Wet weight-to-dry weight ratios after 180 min of perfusion were 5.02 Ϯ 0.57 in APCϩGlb hearts, 5.46 Ϯ 0.86 in APCϩGlb-R hearts, 7.43 Ϯ 0.17 in APCϩGlb/ Glb-R hearts, 7.02 Ϯ 0.66 in GI hearts, 6.24 Ϯ 0.72 in control hearts, and 5.86 Ϯ 0.68 in APC hearts. There was no significant difference in wet weight-to-dry weight ratios between groups.
Role of mitoK ATP channels in APC cardioprotection during ischemia and reperfusion. LVPDP and ϩdP/dt were significantly decreased in APCϩ5-HD and APCϩ5-HD/5-HD-R hearts (P Ͻ 0.05 vs. APC) at 20 min of perfusion (Table 3) . After APC (30 min of perfusion), LVPDP was significantly decreased in APCϩ5-HD and APCϩ5-HD/5-HD-R hearts (P Ͻ 0.05 vs. APC), and LVEDP was significantly increased in APCϩ5-HD and APCϩ5-HD/5-HD-R hearts (P Ͻ 0.05 vs. APC and APCϩ5-HD-R). ϩdP/dt was significantly decreased in APCϩ5-HD/5-HD-R hearts (P Ͻ 0.05 vs. APC) at 30 min of perfusion just before global ischemia. LVPDP and ϩdP/dt were significantly decreased (P Ͻ 0.05 vs. APC) in APCϩ5-HD hearts at the start of reperfusion (70 min of perfusion), but by 20 min of reperfusion (80 min of perfusion), no significant difference was observed compared with APC hearts. LVPDP and ϩdP/dt were significantly decreased (P Ͻ 0.05 vs APC) in APCϩ5-HD-R hearts at the start of reperfusion (70-80 min of perfusion), but by 30 min of reperfusion (90 min of perfusion), no significant difference was observed compared with APC hearts. LVPDP was significantly decreased in APCϩ5-HD/5-HD-R hearts at the start of reperfusion (70-80 min of perfusion) and at the end of reperfusion (180 min of perfusion). ϩdP/dt was significantly decreased in APCϩ5-HD/5-HD-R hearts throughout 120 min of reperfusion (70-180 min of perfusion). There was no significant difference in LVEDP and coronary flow within or between groups during reperfusion (70-180 min of perfusion).
Infarct size, expressed as a percentage of ventricular volume, was significantly increased to 23.7 Ϯ 1.9% in APCϩ5-HD hearts (P Ͻ 0.05 vs. APC and APCϩ5-HD-R, NS vs. GI; Fig. 2 ). Infarct size in APCϩ5-HD-R hearts was 8.2 Ϯ 2.3% (P Ͻ 0.05 vs. GI and APCϩ5-HD, NS vs. APC). Infarct size was significantly increased to 27.3 Ϯ 2.0% in APCϩ5-HD/5-HD-R hearts (P Ͻ 0.05 vs. APC and APCϩ5-HD-R, NS vs. APCϩ5-HD and GI). Wet weight-to-dry weight ratios after 180 min of perfusion were 7.35 Ϯ 0.53 in APCϩ5-HD hearts, 5.99 Ϯ 0.61 in APCϩ5-HD-R hearts, and 6.59 Ϯ 0.19 in APCϩ5-HD/5-HD-R hearts (NS vs. APC and control).
Role of sarcK ATP channels in APC cardioprotection during ischemia and reperfusion. LVPDP and ϩdP/dt were significantly decreased in APCϩHMR hearts (P Ͻ 0.05 vs. APC) at 20 min of perfusion (after 2 min of perfusion of HMR before APC; Table 4 ). After APC (30 min of perfusion), LVPDP and ϩdP/dt were significantly decreased in APCϩHMR hearts (P Ͻ 0.05 vs. Results are shown as means Ϯ SE; n ϭ 6 for each group. Functional data for APC hearts perfused separately with the rabbit heart selective mitoK ATP channel blocker 5-HD for 2 min before APC and during the 5-min reperfusion before global ischemia (APCϩ5-HD) or for 2 min at the onset of reperfusion (APCϩ5-HD-R) or during both periods (APCϩ5-HD/5-HD-R) are shown. Significant differences at P Ͻ 0.05 vs. APC are denoted with an asterisk. No significant differences were observed among APCϩ5-HD, APCϩ5-HD-R, or APCϩ5-HD/ 5-HD-R during 120-min reperfusion (70-180 min of perfusion). APC). LVPDP and ϩdP/dt were significantly decreased (P Ͻ 0.05 vs. APC) in APCϩHMR-R hearts at the start of reperfusion (70-80 min and 70 min of perfusion, respectively), but by 90 min and 80 min of perfusion, respectively, no significant difference compared with APC hearts was observed in APCϩHMR-R hearts. LVPDP was significantly decreased in APCϩHMR hearts throughout reperfusion except at the end of reperfusion (180 min of perfusion). ϩdP/dt was significantly decreased in APCϩHMR hearts at the start of reperfusion (70-90 min of perfusion), but by 120 min of reperfusion, no significant difference compared with APC hearts was observed in APCϩHMR hearts.
When sarcK ATP channels were blocked with HMR-1883 for 2 min before APC and during the 5-min reperfusion before global ischemia (HMR) and for 2 min at the onset of reperfusion (APCϩHMR/HMR-R), LVPDP and ϩdP/dt were significantly decreased throughout reperfusion (70-180 min of perfusion; P Ͻ 0.05 vs. APC).
Combined role of mito-and sarcK ATP channels in APC cardioprotection. To investigate the combined role of mito-and sarcK ATP channels in APC cardioprotection, APC hearts were perfused with 5-HD and HMR-1883 for 2 min before APC and during the 5-min reperfusion before global ischemia and with HMR-1883 for 2 min at the onset of reperfusion (APCϩ5-HD-HMR/HMR-R; Table 4 ). LVPDP and ϩdP/dt were Results are shown as means Ϯ SE; n ϭ 6 for each group. *Significant differences at P Ͻ 0.05 vs. APC hearts; **significant differences at P Ͻ 0.05 vs. GI hearts. No significant difference in infarct size was observed in APCϩ5-HD or APCϩ5-HD/5-HD-R hearts compared with GI hearts. There was no significant difference in infarct size between APCϩ5-HD-R and APC hearts. Results are shown as means Ϯ SE; n ϭ 6 for each group. Functional data for APC hearts perfused separately with the selective sarcK ATP channel blocker HMR-1883 for 2 min before APC and during the 5-min reperfusion before global ischemia (APCϩHMR) or for 2 min at the onset of reperfusion (APCϩHMR-R) or during both periods (APCϩHMR/HMR-R) are shown. Functional data for APC hearts perfused with 5-HD and HMR-1883 for 2 min before APC and during the 5-min reperfusion before global ischemia and for 2 min at the onset of reperfusion (APCϩ5-HD-HMR/HMR-R) are also shown. Significant differences at P Ͻ 0.05 vs. APC are noted with an asterisk. There was no significant difference in LVPDP and ϩdP/dt observed between APCϩHMR/HMR-R and APCϩ5-HD-HMR/HMR-R hearts during 120-min reperfusion (70-180 min of perfusion).
significantly decreased (P Ͻ 0.05 vs. APC; NS vs. GI) throughout reperfusion (70-180 min of perfusion). No significant difference in LVPDP or ϩdP/dt was observed between APCϩ5-HD-HMR/HMR-R and APCϩHMR/HMR-R hearts.
Infarct size was 10.6 Ϯ 1.3% in APCϩHMR, 8.2 Ϯ 2.1% in APCϩHMR-R, and 6.1 Ϯ 1.0% in APCϩHMR/ HMR-R hearts (P Ͻ 0.05 vs. GI and APCϩ5-HD, NS vs. APC and APCϩ5-HD-R; Fig. 3 ). Infarct size was significantly increased to 24.0 Ϯ 2.8% in APCϩ5-HD-HMR/HMR-R hearts (P Ͻ 0.05 vs. APC, APCϩ5-HD-R, APCϩHMR, APCϩHMR-R, and APCϩHMR/HMR-R; NS vs. GI and APCϩ5-HD). Wet weight-to-dry weight ratios after 180 min of perfusion were 7.77 Ϯ 0.97 in APCϩHMR, 7.19 Ϯ 1.00 in APCϩHMR-R, 7.38 Ϯ 0.34 in APCϩHMR/HMR-R, and 6.23 Ϯ 0.24 in APCϩ5-HD-HMR/HMR-R hearts (NS vs. APC and control).
DISCUSSION
Murry et al. (30) were the first to describe an endogenous myocardial protection, IPC, in which the imposition of one or more brief periods of ischemia (3-5 min) followed by reperfusion "preconditions" the heart such that infarct size and myocardial necrosis are significantly reduced during the subsequent induction of sublethal ischemia. The induction of endogenous myocardial protection via preconditioning would appear to be common in all species studied in reducing myocardial infarct volume (19) . In previous reports (24-27, 37, 38), we showed that APC extends the cardioprotection afforded by IPC by both significantly decreasing infarct size (P Ͻ 0.05 vs. IPC) and significantly enhancing postischemic functional recovery (P Ͻ 0.05) in both the in situ and isolated, perfused rabbit heart and the in situ blood-perfused sheep heart. In this report, we have investigated the role of K ATP channels in the isolated, perfused Langendorff heart model, and therefore the effects of neutrophils and plasma-borne inflammatory components on infarct size were not assessed. However, in earlier reports (see Ref. 24) , we showed that the beneficial effects of APC in reducing myocardial infarct size and enhancing postischemic functional recovery are preserved in the in situ blood-perfused heart model, providing cardioprotection after 30-min global ischemia similar to that of cold blood cardioplegia. We (25) also showed that the cardioprotection afforded by APC occurs through the coincident and synergistic action of a bolus injection of adenosine and IPC. IPC or a bolus injection of adenosine, when used independently, decreased infarct size, but this decrease was significantly less than that achieved with APC and did not enhance postischemic functional recovery (25) . Recently, we (25) showed that APC cardioprotection is modulated by adenosine receptors. Our results indicated that APC infarct size reduction was primarily modulated by adenosine receptors before ischemia, whereas significantly APC-enhanced postischemic functional recovery was modulated by adenosine receptors both before ischemia and during reperfusion (25) .
Previous reports indicated that the downstream effector(s) of adenosine receptor activation are the K ATP channels. Gross and Auchampach (12) were the first to show that K ATP channels mediated IPC and that glibenclamide and 5-hydroxydecanoate effectively counteracted these cardioprotective effects. These initial studies performed in the canine model have been repeated by numerous investigators in various animal and human models, and it has been proposed, based on K ATP channel openers that mimic preconditioning and K ATP channel inhibitors that block IPC, that the K ATP channels are central to the mechanism(s) modulating IPC (1, 20, 29, 31, (34) (35) (36) .
Our results shown in Table 2 and Fig. 1 indicate that the cardioprotection afforded by APC is also modulated by K ATP channels. The nonspecific K ATP channel blocker glibenclamide completely blocked APC-enhanced infarct size reduction before ischemia, with infarct size in APCϩGlb hearts being significantly increased such that no significant difference compared with GI hearts was observed. In APCϩGlb-R hearts, infarct size was also increased, but this increase was significantly less (P Ͻ 0.05) than that in APCϩGlb hearts and was significantly less (P Ͻ 0.05) than that observed in GI hearts. Our results also show that blockade of K ATP channels either before ischemia (APCϩGlb) or during reperfusion (APCϩGlb-R) partially modulated postischemic functional recovery; however, when K ATP channels were blocked both before ischemia and during reperfusion (APCϩGlb/ Glb-R), APC-enhanced postischemic functional recovery was significantly decreased.
These results are in agreement with our previous report (25) and that of Gross and Auchampach (12) , who showed that intravenous administration of glibenclamide either before or after a single 5-min period of IPC completely abolished IPC-associated infarct size reduction in dogs. Our results also agree with those of Van Winkle et al. (39) , who showed that cardioprotection provided by adenosine receptor activation was abolished by blockade of K ATP channels, and with those of Toombs et al. (35, 36) , who showed that in the rabbit heart both IPC and protection afforded by adenosine Results are shown as means Ϯ SE; n ϭ 6 for each group. *Significant differences at P Ͻ 0.05 vs. APC hearts; **significant differences at P Ͻ 0.05 vs. GI hearts. pretreatment are abolished by blockade of K ATP channels. Our data also extend the results observed by these groups and indicate that K ATP channel blockade modulates postischemic functional recovery when used before ischemia and/or during reperfusion.
Two K ATP channel subtypes have been shown to exist in the myocardium, with one subtype located in the sarcolemma (sarcK ATP ) and the other in the inner membrane of the mitochondria (mitoK ATP ) (13, 21) . Activation of K ATP channels is hypothesized to be the consequence of ischemia-induced fall of intracellular ATP and activation of adenosine receptors (4, 5, 22, 31, 32, 42) . Under normal conditions, the K ATP channels are closed; this inhibition occurs by free intracellular ATP and Mg 2ϩ -ATP and is responsive to changes in ATP concentration produced by glycolysis but not by increases through application of exogenous ATP (14, 16) . The opening of the sarcK ATP channels during ischemia occurs as intracellular ATP levels fall (not extracellular ATP) and has been postulated to reduce the action potential plateau phase, reduce Ca 2ϩ current, and, therefore, reduce the Ca 2ϩ -related energy cost of contraction (4, 32) . However, Grover et al. (15) showed that when action potential duration is blocked the cardioprotective action (decreased infarct size) of the potassium channel opener cromakalim is maintained, suggesting that the sarcK ATP channels play a role in cardioprotection other than that of infarct size reduction. Support for the separation of the involvement of K ATP channel function in the modulation of infarct size reduction and enhanced functional recovery comes from the experiments of Garlid et al. (10) and the recent studies of Liu et al. (21) , who showed that the mitoK ATP channels, but not sarcK ATP channels, modulate cell viability. To investigate the role of mito-and sarcK ATP channels in APC cardioprotection we have used 5-hydroxydecanoate, shown to be a mitoK ATP -specific channel blocker in the rabbit, and the cardioselective sarcK ATP channel blocker HMR-1883 (2, 3, 11, 13, 33) .
In previous studies by others in which the mechanism of IPC has been investigated, K ATP channel blockers were perfused before IPC (1, 12, 36, 39) . In our studies K ATP channel blockers were perfused both before and after APC. This protocol was incorporated after initial experiments indicated that the use of K ATP channel blockers only before APC had variable effects on the cardioprotection afforded by APC. We speculate that these results were caused by the bolus injection of adenosine, which competitively inhibited the action of the K ATP channel blockers.
Our results show that infarct size, expressed as a percentage of ventricular volume, was significantly increased to 23.7 Ϯ 1.9% in APCϩ5-HD hearts (P Ͻ 0.05 vs. APC and 5-HD-R, NS vs. GI; Fig. 2 ). These results indicate that mitoK ATP channel blockade before ischemia (APCϩ5-HD) completely abolished APC-enhanced myocardial infarct size reduction (P Ͻ 0.05 vs. APC and APCϩ5-HD-R, NS vs. GI), whereas mitoK ATP channel blockade during reperfusion (APCϩ5-HD-R) had no effect on APC-enhanced myocardial infarct size reduction. MitoK ATP channel blockade both before ischemia and during reperfusion (APCϩ5-HD/5-HD-R) also completely abolished APC-enhanced myocardial infarct size reduction (P Ͻ 0.05 vs. APC and APCϩ5-HD-R, NS vs. GI). Of significance, our results shown in Table 3 indicate that APCϩ5-HD, APCϩ5-HD-R, and APCϩ5-HD/5-HD-R treatments had only transient effect on APC postischemic functional recovery (70-80 min of perfusion) and that, after 30 min of reperfusion (90 min of perfusion), there was no significant difference in LVPDP, LVEDP, or ϩdP/dt among APCϩ5-HD, APCϩ5-HD-R, APCϩ5-HD/5-HD-R, and APC hearts. These results suggested that mitoK ATP channels were involved in the mechanism modulating APC-enhanced infarct size reduction and that this modulation occurred primarily during ischemia. These results further suggested that mitoK ATP channel blockade either before ischemia and/or during reperfusion had no effect on APC-enhanced postischemic functional recovery. We speculate that as infarct size is increased the effect on postischemic functional recovery is also increased. The relative level at which a stoichiometric relationship exists requires further investigation and cannot be answered in this report.
Examination of the role of sarcK ATP channels using the cardiospecific sarcK ATP channel blocker HMR-1883 (2, 3, 11, 13) indicated that APC-enhanced postischemic functional recovery, shown in Table 4 , was partially abolished by sarcK ATP channel blockade before ischemia (APCϩHMR) and partially abolished by sarcK ATP channel blockade during reperfusion (APCϩHMR-R). However, blockade of sarcK ATP channels both before ischemia and during reperfusion (APCϩHMR/HMR-R) significantly decreased APC-enhanced postischemic functional recovery throughout reperfusion (P Ͻ 0.05 vs. APC and APCϩ5-HD/5-HD-R, NS vs. GI). No significant difference was observed in infarct size among APCϩHMR, APCϩHMR-R, and APCϩHMR/HMR-R hearts compared with APC hearts. These results are in agreement with the findings of Garlid et al. (10) and Liu et al. (21) .
To confirm the role of mito-and sarcK ATP channels in cardioprotection, APC hearts were perfused with 5-HD and HMR-1883 for 2 min before APC and during the 5 min after APC, before global ischemia, and with HMR-1883 for 2 min at the onset of reperfusion (APCϩ5-HD-HMR/HMR-R). This protocol blocked mitoK ATP channels before ischemia and sarcK ATP channels before ischemia and during reperfusion. Our results shown in Table 4 and Fig. 3 indicate that LVPDP and ϩdP/dt in APCϩ5-HD-HMR/HMR-R hearts were significantly decreased (P Ͻ 0.05 vs. APC and APCϩ5-HD/5-HD-R) during reperfusion (70-180 min of perfusion), that infarct size was significantly increased in APCϩ5-HD-HMR/HMR-R hearts (P Ͻ 0.05 vs. APC, APCϩ5-HD-R, APCϩHMR, APCϩHMR-R, and APCϩHMR/HMR-R), and that these values were not significantly different from those observed in GI hearts. These data are in agreement with our earlier reports and confirm that using specific K ATP channel blockade to block both mito-and sarcK ATP channels before ischemia and sarcK ATP channels during reperfusion completely abolishes the cardioprotection afforded by APC, producing the same effects seen in GI hearts (NS vs. GI). These results also confirm that infarct size is primarily modulated before ischemia and that postischemic functional recovery is modulated both before ischemia and during reperfusion.
Our results indicate that there is a separation of the mechanisms modulating infarct size and functional recovery. The separation of the involvement of K ATP channel function in the modulation of infarct size reduction and enhanced functional recovery was previously suggested by Garlid et al. (10) and the recent studies of Liu et al. (21) , who showed that the mitoK ATP channels, but not sarcK ATP channels, modulate cell viability. Our data suggest that in APC cardioprotection K ATP channels (sarcK ATP and mitoK ATP ) are opened during the preconditioning phase, in agreement with the earlier investigations of Gross and Auchampach (12) and Auchampach et al. (1), who suggested that the opening of the K ATP channels not only triggers IPC but is also involved with the memory phase of IPC. Opening the sarc-and mitoK ATP channels would allow for the influx of K ϩ to the cytoplasm and the mitochondrion and would attenuate cytosolic calcium (Ca i 2ϩ ) and mitochondrial calcium (Ca mito 2ϩ ) accumulation. The modulation of infarct size would presumably occur through the modulation of Ca mito 2ϩ accumulation and the preservation of mitochondrial function.
Increased Ca mito 2ϩ accumulation has been shown to destabilize the inner mitochondrial membrane, causing the inner membrane pore to open, which permits further movement of cations across the mitochondrial membrane (8) . The opening of these pores renders the mitochondrion incapable of synthesizing ATP and has been suggested to be a key event in the process leading to myocardial cell death (23) . We speculate that these events are directly related to infarct size reduction. Support for this hypothesis comes from earlier reports by us (6, 7) and the recent investigation of Fryer et al. (9) , who showed that mitoK ATP channels play an important role in the preservation of mitochondrial function. We speculate that the opening of the mitoK ATP channels before ischemia effectively obviates Ca mito 2ϩ accumulation. The opening of the sarcK ATP channels would allow for Ca i 2ϩ accumulation, but Ca mito 2ϩ accumulation would not occur, thus allowing for the preservation of mitochondrial function and cell integrity.
Recently we showed (37) that APC has anti-stunning effects and that although the anti-infarct effects of APC are significantly extended the anti-stunning effects are transient. These data would suggest that, although the opening of sarcK ATP channels during ischemia and reperfusion may allow for decreased Ca i 2ϩ accumulation, mechanisms other than sarcK ATP channels are involved in the enhancement of postischemic functional recovery.
